Table 2.
Examples of targeted therapies currently undergoing clinical testing in NSCLC
| Study name/identifiera | Purpose | Targeted therapies |
|---|---|---|
| Pilot trial of molecular profiling and targeted therapy for advanced NSCLC, SCLC, and thymic malignancies NCT01306045 |
Evaluate the ability of genetic analysis to determine targeted therapy for patients with NSCLC | AZD6244 MEK1 inhibitor for KRAS or BRAF mutations |
| MK-2206 AKT inhibitor for PIK3CA, AKT, PTEN mutations | ||
| Sunitib inhibitor for KIT or PDGFRA mutations | ||
| Lapatinib inhibitor for ERBB2 | ||
| Erlotinib inhibitor for EGFR mutations | ||
| Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic NSCLC NCT02117167 |
Evaluate the use of high throughput genome analysis to determine administration of targeted therapy according to genetic profile of the tumor compared to standard treatment. Randomized multicenter Phase II trial | AZD2014 inhibitor for m-TOR |
| AZD4547 inhibitor for FGFR | ||
| AZD5363 inhibitor for AKT, | ||
| AZD8931 inhibitor for EGFR | ||
| Selumetinib inhibitor for MEK1 | ||
| Vandetanib inhibitor for VEGFR and EGFR | ||
| FGFR1 amplification as a predictor of efficacy in a biomarker-driven phase II study of BIBF 1120 in advanced lung SCC patients who have failed up to 2 prior chemotherapeutic regimens NCT01948141 |
Evaluate efficacy of nintedanib in treating patients with advanced NSCLC who failed up to two previous chemotherapy regimens and use of FGFR1 gene copy number is a predictive biomarker | Nintedanib TKI for FGFR1 |
AKT v-akt murine thymoma vial oncogene homolog 1, BRAF v-raf murine sarcoma viral oncogene homolog B, EGFR epidermal growth factor receptor, FGFR1 fibroblast growth factor receptor 1, KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, MEK mitogen-activated protein kinase kinase 1, m-TOR mechanistic target of rapamycin, NSCLC non-small cell lung carcinoma, SCC squamous cell carcinoma, SCLC small cell lung carcinoma, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor
aDenotes http://www.clinicaltrials.gov identifier